Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ERNA Relative to the S&P 500

ERNA Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Eterna Therapeutics Inc. (NASD:ERNA) seasonal charts above shows that a Buy Date of December 27 and a Sell Date of March 16 has resulted in a geometric average return of 10.51% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 110.51% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various?cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

To download ERNA seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ERNA